Targeted Oncology1h
FDA Considers TAR-200 in BCG-Unresponsive High-Risk NMIBC
An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...
J&J Initiates Bid for FDA Approval of TAR-200 in Bladder Cancer
The New Brunswick, N.J., pharmaceutical giant said the FDA accepted the application through its Real-Time Oncology Review program, which allows for an earlier submission of topline efficacy and safety ...
Targeted Oncology1d
LYT-200 Gains FDA Fast Track Status in Acute Myeloid Leukemia
LYT-200 now has gained fast track designation from the FDA in acute myeloid leukemia in addition to its prior designation for ...